<DOC>
	<DOCNO>NCT00957684</DOCNO>
	<brief_summary>This phase III 4-part study multiple centre . Part I 26-week parallel-group , randomise , placebo-controlled period ( 8 week single-blind placebo baseline , 2 week double-blind titration , 12 week maintenance , 4 week taper ) . After complete baseline period , patient randomise 1:1:1:1 ratio 1 3 ESL dose level placebo . Part II 1-year open-label extension patient complete Part I . The start dose 800 mg daily could titrate 400-mg interval 400 1200 mg. Part III additional 1-year open-label extension patient complete Part II , participate post-Part II study extension , allow patient continue treatment ESL , continue take ESL compassionate use program . ESL start dos receive end Part II , post-Part II study extension , compassionate use , could titrate 400-mg interval 400 1200 mg daily . Part IV study extension allow patient continue ESL treatment end Part III marketing authorisation discontinuation clinical development .</brief_summary>
	<brief_title>Efficacy Safety Eslicarbazepine Acetate Adjunctive Therapy Refractory Partial Seizures</brief_title>
	<detailed_description>Duration Treatment : The duration Part I 26 week : 8 week placebo run-in , 2 week dose titration , 12 week maintenance , 4 week tapering-off period . The duration Part II 1 year . The duration Part III plan 1 year ( patient treat &gt; 1 year ) . The duration Part IV &gt; 3 year ( patient could continue treatment ESL market availability ) .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>write informed consent sign patient age 18 year document diagnosis simple complex partial seizure without secondary generalisation since least 12 month prior screen least 4 partial seizure 4 week period last 8 week prior screen , currently treat 1 2 AEDs ( except oxcarbazepine felbamate ) , stable dose regimen least 2 month prior screen ( patient use vigabatrin medication least 1 year deficit visual field identify ) except epilepsy , patient judge general good health base medical history , physical examination laboratory test postmenopausal otherwise incapable become pregnant reason surgery tubal ligation ; case woman childbearing potential , patient must present serum betahCG test consistent nongravid state agree remain abstinent use reliable contraception ( oral contraception combine barrier method ) simple partial seizure motor symptomatology ( classified A24 accord International Classification Epileptic Seizures ) videoEEG document primarily generalise epilepsy know rapid progressive neurological disorder ; history status epilepticus cluster seizure ( i.e. , 3 seizure within 30 minute ) within 3 month prior screen seizure psychogenic origin within last 2 year history schizophrenia suicide attempt currently exposure felbamate oxcarbazepine within one month screen use benzodiazepine occasional basis ( except use chronically AED ) previous use ESL participation clinical study ESL know hypersensitivity carbamazepine , oxcarbazepine chemically related substance history abuse alcohol , drug medication within last 2 year uncontrolled cardiac , renal , hepatic , endocrine , gastrointestinal , metabolic , haematological oncology disorder second thirddegree atrioventricular blockade correct pacemaker relevant clinical laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>refractory</keyword>
	<keyword>partial</keyword>
	<keyword>epilepsy</keyword>
</DOC>